Lipum AB
Clinical-stage biopharma developing novel treatments for chronic inflammatory diseases.
LIPUM | ST
Overview
Corporate Details
- ISIN(s):
- SE0015660899 (+1 more)
- LEI:
- 549300V7JL0004BHBD93
- Country:
- Sweden
- Address:
- Tvistevägen 48 C, 907 36 Umeå
- Website:
- https://lipum.se/
Description
Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel treatments for chronic inflammatory diseases. The company's lead drug candidate, SOL-116, is a humanized antibody designed to offer a unique, first-in-class mechanism of action by targeting the protein bile salt-stimulated lipase (BSSL). Lipum has successfully completed a Phase 1 clinical trial for SOL-116, which evaluated its safety and tolerability, supporting its continued development for rheumatoid arthritis (RA). The company also explores the potential application of its treatment for other inflammatory diseases with significant unmet medical needs, aiming to improve the quality of life for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lipum AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lipum AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lipum AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-14 | Peter Hovstadius | Other | Sell | 2,000 | 28,260.00 SEK |
| 2025-04-14 | Peter Hovstadius | Other | Sell | 1,500 | 22,770.00 SEK |
| 2025-04-14 | Peter Hovstadius | Other | Sell | 1,500 | 21,030.00 SEK |
Peer Companies
